转移性肾癌一线治疗药物舒尼替尼、索拉非尼和培唑帕尼的药物经济学评价文献研究  

Literature Study on Pharmacoeconomics Evaluation of First-line Therapy Drugs for Metastatic Renal Carcinoma as Sunitinib,Sorafenib and Pezopanib

作　　者：刘海娇 吴玉霞 徐伟[1] LIU Haijiao;WU Yuxia;XU Wei(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学国际医药商学院

出　　处：《中国药房》2020年第5期612-616,共5页China Pharmacy

摘　　要：目的:评估转移性肾癌一线治疗药物舒尼替尼、索拉非尼和培唑帕尼的经济性,为医保目录调整、临床用药决策提供参考依据。方法:以"转移性肾癌""舒尼替尼""索拉非尼""培唑帕尼""成本-效果""成本-效用""成本-效益""经济性分析"等为中文检索词,以"Metastatic renal cell carcinoma""m RCC""Sunitinib""Sorafenib""Pazopanib""Cost-effectiveness""Cost-utility""Cost-benefit""Economic analysis"等为英文检索词,在PubMed、Web of Science、the Cochrane Library、中国知网、万方数据库及维普网等数据库中检索2006年1月1日-2019年7月15日公开发表的相关文献,按照纳入排除标准筛选文献。使用卫生经济学评价报告标准共识(CHEERS)量表对纳入文献进行质量评价,提取相关数据后定性比较舒尼替尼、索拉非尼、培唑帕尼治疗转移性肾癌的有效性和经济性。结果:纳入文献10篇,7篇文献的总符合率均在75.00%以上。其中,对比舒尼替尼与索拉非尼方案的4篇文献研究中,3篇文献研究指出舒尼替尼为绝对优势方案,1篇文献研究指出索拉非尼更有经济性;对比舒尼替尼与培唑帕尼方案的6篇文献研究中,4篇文献研究指出培唑帕尼为绝对优势方案,2篇文献研究指出舒尼替尼更有经济性。结论:大多数情况下,培唑帕尼治疗转移性肾癌的有效性和经济性强于舒尼替尼和索拉非尼,但真实世界数据的研究显示舒尼替尼更有经济性。OBJECTIVE:To evaluate the economics of first-line therapy drug for metastatic renal cell carcinoma(mRCC)as sunitinib,sorafenib and pazopanib,and to provide reference for the adjustment of medical insurance list and clinical medication decision. METHODS:Using"metastatic renal cell carcinoma""mRCC""sunitinib""sorafenib""pazopanib""cost-effectiveness""cost-utility""cost-benefit"" economic analysis"as the Chinese and English retrieval words,relevant literatures published during Jan. 1st,2006 to Jul. 15th,2019 were retrieved from PubMed,Web of Science,the Cochrane Library,CNKI,Wanfang database,VIP. The literatures were screened according to inclusion and exclusion criteria. The quality of the included literatures was evaluated with CHEERS scale. The effectiveness and economy of sunitinib,sorafenib and pezoparib in the treatment of mRCC were compared qualitatively after the relevant data were extracted. RESULTS:A total of 10 literatures were included,and the total coincidence rates of 7 literatures over 75.00%. Among the 4 literature studies of sulatinib vs. sorafenib,3 literature studies pointed out that sulatinib was the absolute advantage scheme,and 1 literature study pointed out that sorafenib was more economical;among the 6 literature studies of sunitinib vs. pezoparib,4 literature studies indicated that pezoparib was the absolute advantage scheme,and 2 literature studies indicated that sunitinib was more economical. CONCLUSIONS:In most cases,the efficacy and economy of pezoparib in the treatment of m RCC is better than sunitinib and sorafenib,but real world data shows that sunitinib is more economical.

关 键 词：舒尼替尼 索拉非尼 培唑帕尼 药物经济学评价 文献研究 系统评价 

分 类 号：R956[医药卫生—药学]